Tenofovir alafenamide fumarate B

Research use only, not for human use.

Tenofovir alafenamide fumarate (GS-7340 fumarate) is an orally available precursor of Tenofovir with anti-HIV activity, used to prevent HIV infection.

Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral proagent of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor.

Tenofovir alafenamide fumarate (GS-7340 fumarate) antiviral activities are similar across all cell types, ranging from 5 to 7 nM, while the CC50 varies from 4.7 to 42 μM for MT-4 and MT-2 cells, respectively. The antiviral activity of TAF is evaluated against a panel of HIV-1 and HIV-2 isolates, including HIV-1 group M subtypes A to G, as well as group N and O isolates. Overall, for the 29 primary HIV-1 isolates tested in PBMCs, TAF EC50s range from 0.1 to 12 nM, with a mean EC50 of 3.5 nM compared to a mean EC50 of 11.8 nM for AZT, which is used as an internal control. For the HIV-2 isolates, the mean EC50s are 1.8 nM for TAF and 6.4 nM for AZT.

Tenofovir alafenamide fumarate (GS-7340 fumarate) is an amidate prodrug of Tenofovir with good oral bioavailability and increases plasma stability compared to Tenofovir disoproxil fumarate (TDF).

——

Microbiology/Virology

HIV

HIV Protease

——

——

379270-38-9

592.54

C25H33N6O9P

>98% (HPLC)

In Vitro:?DMSO : ≥ 36 mg/mL (60.76 mM; )H2O : ≥ 25 mg/mL (42.19 mM)

OC(=O)\C=C\C(O)=O.CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)Oc1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years